| Treating Chronic Mutational
Hepatitis B with Chinese Medicine Vitalliver (Vigconic Suppositories)
by: ZHANG GUAN HUA, LIANG CHAO, ZHENG WAN PIN
Treating chronic mutational hepatitis B with Chinese medicine
Vitalliver (Vigconic suppositories)
ZHANG GUAN HUA, LIANG CHAO, ZHENG WAN PIN
Chengdu University of TCM, Hepatitis Laboratory in the attached
hospital of Chengdu University of TCM, Sichuan, China
Research Method:
Quantitative determination by contrasting HBV-DNA of cases
before and after the treatment.
Number of cases: 25 (n)
Case Selection: Between the age of 16 and 65, in accordance
with the diagnosis standards pf chronic Hepatitis B, with
negative e antigen and positive e antibody, HBV-DNA > 1×104
cp/mL.
Detection Method: All the blood samples are detected by Sichuan
Clinical Detection Center; PCR-ELISA quantitative determination
is used within detection range of 1×104 - 1×107-8,
HBV-DNA, unit of measurement is cp/mL.
Direction Plan: one suppository provided by Vigconic (International)
Ltd. Bid. The course of treatment is six months, the tracing
observation after withdrawal lasts six months.
Observation index:
1. HBV-DNA response after the treatment.
2. Lasting HBV-DNA response (six months after withdrawal).
Criterion of Therapeutic Effect:
1. If HBV-DNA volume 1×104 cp/mL: 4/25 (16%)
2. Lasting response:
HBV-DNA volume 1×104 cp/mL: 2/25 (8%)
Among the results of lasting response, 16 blood serum samples
are detected through fluorimetric quantitative determination
PCR by the instruments of PE.USD, H-7700 in the second attached
hospital of Guangzhou Medical College. The result is in accordance
with that in Sichuan Clinical Testing Center. (8 cases among
it < 1×102 cp/mL). The testing range of this testing
method is 1×102 - 1×107-8 cp/mL.
Conclusion
The reason for the repeatedly abnormal liver function of
Chronic Hepatitis B (CHB) patients lies in the repeatedly
duplication of HBV after infection, which leads to fibrosis
of liver, then cirrhosis and liver cancer. It is commonly
accepted that if CHB shows the transformation of HBeAg/Anti-HBe,
HBV-DNA becoming negative, liver function returning to normal
state, the disease is relieved. However, parts of patients
with the transformation of HBeAg/Anti-HBe still remain positive
in HBV-DNA and the pathological change in the liver continues.
Because HBV-DNA occurs promoter mutation in the anterior C
section (1896 necleoside G-A variation) or in the C section
(1762 nucleoside T variation, 1764 G-A variation), HBeAg cannot
come into being. Therefore, the HBeAg in the patient’s
blood cannot be detected, while the virus can keep on duplicating
and fixing itself. Through sequential assay of nucleic acid,
it proves that promoter mutation appears in 30%-60% of HBeAg
negative Chronic Hepatitis B (CHB) in the anterior C section
or in the C section. In some provinces and cities of the People
of China, the percentage of promoter mutation appears in HBeAg
negative Chronic Hepatitis B (CHB) in the anterior C section
or in the C section is from 17.6% to 78.9%. Eight out of the
25 cases of our observation go through the sequential assay
of nucleic acid carried out by the Department of Microbiology
of the University of Hong Kong. It all proves to have HBV-DNA
mutation. The chronic mutational Hepatitis B is infectious
and apt to cause cirrhosis and liver cancer since the present
medicines of antivirus and immuno-modulator do not produce
the expected therapeutic effects.
Vitalliver suppository is made up from a formula of Chinese
herbs, including Ginseng, Deer Horn, Cordyceps, Radix Astragali,
Frudctus Cnidii, Semen Cuscutae, etc. The formula is mainly
for strengthening the body resistant and primarily for reinforcing
Kidney Qi, which produces good therapeutic effects in treating
chronic mutational Hepatitis B. The mechanism is probably
that through the regulating of immune system, the duplication
of virus is inhibited and meanwhile the liver is protected,
so it can produce a lasting therapeutic effect. No adverse
reaction and severe accident happens during clinical observation,
so it is safe for using. Vitalliver is bringing hopes to the
treatment of chronic mutational Hepatitis B.
* The second stage of clinical trial would be carrying out
by the Microbiology Department of the University of Hong Kong
and Chengdu University of Traditional Chinese Medicine.
For more information, please visit: http://www.vigconic.com
Or, contact:
William Yip cs@vigconic.com
5/F, Cheung Wah Building, Sheung Heung Rd,
Kowloon, Hong Kong
Tel: 852-27656200
Fax: 852-27645314
About The Author
Chengdu University of TCM, Hepatitis Laboratory in the attached
hospital of Chengdu University of TCM, Sichuan, China
webmaster@vigconic.com
|
